- Home
- GIGM vs ASBP Comparison
GIGM vs ASBP Comparison
Compare GIGM & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GIGM
- ASBP
- Stock Information
- Founded
- GIGM 1998
- ASBP 2021
- Country
- GIGM Taiwan
- ASBP United States
- Employees
- GIGM N/A
- ASBP N/A
- Industry
- GIGM Computer Software: Programming Data Processing
- ASBP Biotechnology: Pharmaceutical Preparations
- Sector
- GIGM Technology
- ASBP Health Care
- Exchange
- GIGM Nasdaq
- ASBP Nasdaq
- Market Cap
- GIGM 17.8M
- ASBP 18.9M
- IPO Year
- GIGM 2000
- ASBP N/A
- Fundamental
- Price
- GIGM $1.58
- ASBP $0.11
- Analyst Decision
- GIGM
- ASBP
- Analyst Count
- GIGM 0
- ASBP 0
- Target Price
- GIGM N/A
- ASBP N/A
- AVG Volume (30 Days)
- GIGM 6.8K
- ASBP 18.1M
- Earning Date
- GIGM 10-30-2025
- ASBP 11-24-2025
- Dividend Yield
- GIGM N/A
- ASBP N/A
- EPS Growth
- GIGM N/A
- ASBP N/A
- EPS
- GIGM N/A
- ASBP N/A
- Revenue
- GIGM $3,397,000.00
- ASBP N/A
- Revenue This Year
- GIGM N/A
- ASBP N/A
- Revenue Next Year
- GIGM N/A
- ASBP N/A
- P/E Ratio
- GIGM N/A
- ASBP N/A
- Revenue Growth
- GIGM 10.11
- ASBP N/A
- 52 Week Low
- GIGM $1.38
- ASBP $0.09
- 52 Week High
- GIGM $1.89
- ASBP $15.80
- Technical
- Relative Strength Index (RSI)
- GIGM 39.01
- ASBP 26.13
- Support Level
- GIGM $1.58
- ASBP $0.32
- Resistance Level
- GIGM $1.66
- ASBP $0.31
- Average True Range (ATR)
- GIGM 0.04
- ASBP 0.06
- MACD
- GIGM -0.01
- ASBP -0.03
- Stochastic Oscillator
- GIGM 21.41
- ASBP 3.31
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.
About ASBP Aspire Biopharma Holdings Inc.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.